Authors
Heidi H Chang, Tina Yi Jin Hsieh, Katharine M Esselen, Michele R Hacker, Kaitlin Nicholson, Joseph A Dottino
Published in
Gynecologic oncology. Volume 215. Pages 58-63. Oct 31, 2026. Epub Oct 31, 2026.
Abstract
Most endometrial cancers (EC) are obesity-related; yet, there is little known about utilization of glucagon-like peptide-1 receptor agonist (GLP-1RAs), which are effective weight loss medications, in EC.
This is a retrospective cohort study using TriNetX US Collaborative Network, a de-identified, longitudinal electronic health record dataset. Female patients were identified from 1/1/2018-4/15/2024 with BMI ≥30 and grouped by presence or absence of EC diagnosis. Patients were followed for two years or up to 4/15/26, whichever came first. These two groups were 1:1 propensity score matched for demographics, BMI, and comorbidities. Patients with prior bariatric surgery or GLP-1RA use were excluded. The primary outcome was GLP-1RA use. Subgroup analysis was conducted among patients with BMI ≥40.
From 2018 to 2024, GLP-1RAs use in both cohorts increased. However, utilization was consistently lower among patients with EC. In 2018, GLP-1RA use was 1.0% among patients with EC vs. 1.2% among those without EC (RR 0.82, CI 0.60-1.13). By 2024, use increased to 7.8% and 10.6%, respectively (RR 0.73, CI 0.61-0.87). Similar findings were observed among patients with a BMI ≥40, with significantly faster uptake of GLP-1RAs among women without EC.
Patients with EC were less likely to receive GLP-1RAs than matched patients without EC despite obesity being a major risk factor for EC. These findings highlight a potential gap in obesity management among EC survivors and support further investigation of the safety and efficacy of GLP-1RAs in this population.
PMID:
42966334
Bibliographic data and abstract were imported from PubMed on 01 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0